Atezolizumab Monoclonal Antibody from United States
Atezolizumab is a humanized IgG1 monoclonal antibody that blocks PD-L1 and is used in the treatment of bladder cancer and other malignancies. Imported as an unmixed bulk substance without measured doses or retail packaging, it falls under tariff item 3002.13.00 as an immunological product obtained by biotechnological processes.
Duty Rate — United States → Canada
0%
Import Tips
• Confirm the product is free of any added stabilizers or solvents to maintain classification under the unmixed subheading
• Keep certificates of analysis and biotechnological production records for CBSA verification
• Check if the product requires pre-import notification under Health Canada's framework for biologics